Glenda Mary Davison

Prof. Glenda Mary Davison

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2000 in Transplantation
Verified
Journal Article
Closed access
GDGlenda Mary Davison
Glenda Mary Davison
NNNicolas Novitzky
Nicolas Novitzky
AKAlmaree Kline
Almaree Kline
VTValda Thomas
Valda Thomas
LALouise Abrahams
Louise Abrahams
HWHerman Waldmann
Herman Waldmann
Immune reconstitution following transplantation in individuals who had received T-cell-depleted marrow from HLA identical siblings was serially documented and correlated with the clinical recovery. Patients were preconditioned with radiation containing programs. GvHD prophylaxis was by T-cell depletion with CAMPATH 1G (ex vivo; median dose 20 mg). After transplantation lymphoid development was studied by flowcytometry and serum Ig concentrations were determined. Charts were reviewed to determine the effects of the immune reconstitution on the clinical performance. The mean donor mononuclear cell number infused was 0.89×108/kg. Within 6 months all the patients recovered their blood parameters and only one required therapy for GvHD. However, despite normal blood counts, 15 suffered life-threatening opportunistic infections, developing at a median of 24 weeks post grafting, but occurring even after 11 months. At 8 weeks from marrow infusion when leukocyte values had normalized in 15/20, compared to normal, immunophenotyping of blood cells from BMT revealed a significantly reduced mean lymphocyte count (1.06, SD 0.83×109/l;P =0.01), cells expressing CD3 (0.7×109/l, SD 0.68;P =0.05), CD4 (0.13×109/l, SD 0.21;P =0.0001) and CD19 (0.04×109/l, SD 0.05;P =0.001). Populations expressing CD8 and CD56 remained within normal range throughout the study. Normalization of cell numbers displaying CD2, CD3 and CD19 was delayed until 52, 52 and 24 weeks respectively, while CD4 counts persisted subnormal even at 72 weeks. Serum IgA levels were significantly decreased for the entire study period. T-cell depletion with CAMPATH 1G while effectively preventing GvHD, also causes clinically significant and prolonged immunosuppression with apparently important clinical implications.

1 December 2002 in Transplantation
Verified
Journal Article
Closed access
NNNicolas Novitzky
Nicolas Novitzky
GDGlenda Mary Davison
Glenda Mary Davison
GHGeoffrey Hale
Geoffrey Hale
HWHerman Waldmann
Herman Waldmann
Compared with allogeneic bone marrow, in cytokine mobilized blood stem cell grafts, the number of hematopoietic progenitors and lymphoid cells is higher. Consequently, we compared the immune reconstitution following these two transplant modalities in patients receiving T-cell depleted grafts for hematological malignancies and studied the impact of lymphocyte subset recovery on clinical outcome. Conditioning for transplantation was radiation-based, while graft versus host disease prophylaxis was by ex vivo T-cell depletion with Campath-1 antibodies. Clinical parameters of patients receiving bone marrow or cytokine-mobilized progenitor cell transplants were reviewed with emphasis placed on defining infectious events and on the causes of treatment failure (relapse, graft failure, or any cause of death). The blood lymphoid subsets, as well as markers for memory and naive T cells, were sequentially studied by standard flow cytometry. Serum immunoglobulins (Ig) concentrations were also determined. The patient population included 15 females and 27 males with a median age of 32.5 (range 15-54) years. Source of human leukocyte antigen-identical sibling allogeneic grafts was bone marrow in 14 and peripheral blood (PBPC) in 28. The median follow-up was of 1,278 (range 47-2,466) days. Following hematopoietic recovery, within the first year, 28 patients were readmitted for pyrexial episodes, and four died of sepsis. In both groups, while the CD8+ subset recuperated rapidly, CD19 and CD4+ T cells remained significantly decreased even after 12 months, leading to persistently abnormal CD4:CD8 ratios. The median values of CD16+ and CD56+ (natural killer) cells remained normal throughout the study period. Despite the patients who were receiving PBPC grafts having significantly higher numbers of allogeneic mononuclear cells (x 10(8)/kg; median: 6.97; range 4.03-10.10 vs. 0.71; range 0.45-0.99; P<0.001) and colony-forming unit granulocyte-macrophages (CFU-GMs) (x 10(4)/kg; median: 27.75; range 0-196, 2 vs. 13.05; range 2.43-57; P<0.05), the recovery rate of B cells or T-cell subpopulations was similar to those receiving bone marrow transplantation (BMT). Double fluorescence studies showed that CD2/CD45RO and RA as well as CD4/CD45RO and RA remained subnormal even after 12 months follow-up. During the observation period, except for IgA, normal levels of immunoglobulins were detected. In all, 18 out of 42 patients failed therapy, and 14 patients died. Treatment failure occurred at a median of 270 (range 47-1,638) days and was significantly associated with low total lymphocyte count (P = 0.01), CD2 (P = 0.09), CD8 (P = 0.01), CD19 (P = 0.02), CD45RA (P = 0.05), and CD4/CD45RA (P = 0.01), when tested at 6 months from transplantation. After T-cell depleted allogeneic PBPC or BMT, no differences in the rate of immune recovery were detected. However, patients with specific subset abnormalities at 6 months from grafting had a significantly higher risk of treatment failure.


29 August 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
FAFlorence Ifechukwude Aboderin
Florence Ifechukwude Aboderin
TOTaofeeq Oduola
Taofeeq Oduola
GDGlenda Mary Davison
Glenda Mary Davison
OOOluwafemi Oguntibeju
Oluwafemi Oguntibeju
Sickle cell anaemia (SCD) is a life-threatening haematological disorder which is predominant in sub-Saharan Africa and is triggered by a genetic mutation of the β-chain haemoglobin gene resulting in the substitution of glutamic acid with valine. This mutation leads to the production of an abnormal haemoglobin molecule called haemoglobin S (HbS). When deoxygenated, haemoglobin S (HbS) polymerises and results in a sickle-shaped red blood cell which is rigid and has a significantly shortened life span. Various reports have shown a strong link between oxidative stress, inflammation, the immune response, and the pathogenesis of sickle cell disease. The consequence of these processes leads to the development of vasculopathy (disease of the blood vessels) and several other complications. The role of the immune system, particularly the innate immune system, in the pathogenesis of SCD has become increasingly clear in recent years of research; however, little is known about the roles of the adaptive immune system in this disease. This review examines the interaction between the immune system, inflammation, oxidative stress, blood transfusion, and their effects on the pathogenesis of sickle cell anaemia.

1 September 1999 in Transplant Immunology
Verified
Journal Article
Closed access
VQValerie Quesniaux
Valerie Quesniaux
LFLynn Fullard
Lynn Fullard
HAHiram Arendse
Hiram Arendse
GDGlenda Mary Davison
Glenda Mary Davison
NMNoel Markgraaff
Noel Markgraaff
HSHenk-Jan Schuurman
Henk-Jan Schuurman

26 May 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
CWCecil Jack Weale
Cecil Jack Weale
DMDon Matshazi
Don Matshazi
SDSaarah Davids
Saarah Davids
Shanel RaghubeerShanel Raghubeer
Shanel Raghubeer
RERajiv Erasmus
Rajiv Erasmus
TMTandi E Matsha
Tandi E Matsha
This cross-sectional study investigated the association of miR-1299, -126-3p and -30e-3p with and their diagnostic capability for dysglycaemia in 1273 (men, n = 345) South Africans, aged >20 years. Glycaemic status was assessed by oral glucose tolerance test (OGTT). Whole blood microRNA (miRNA) expressions were assessed using TaqMan-based reverse transcription quantitative-PCR (RT-qPCR). Receiver operating characteristic (ROC) curves assessed the ability of each miRNA to discriminate dysglycaemia, while multivariable logistic regression analyses linked expression with dysglycaemia. In all, 207 (16.2%) and 94 (7.4%) participants had prediabetes and type 2 diabetes mellitus (T2DM), respectively. All three miRNAs were significantly highly expressed in individuals with prediabetes compared to normotolerant patients, p < 0.001. miR-30e-3p and miR-126-3p were also significantly more expressed in T2DM versus normotolerant patients, p < 0.001. In multivariable logistic regressions, the three miRNAs were consistently and continuously associated with prediabetes, while only miR-126-3p was associated with T2DM. The ROC analysis indicated all three miRNAs had a significant overall predictive ability to diagnose prediabetes, diabetes and the combination of both (dysglycaemia), with the area under the receiver operating characteristic curve (AUC) being significantly higher for miR-126-3p in prediabetes. For prediabetes diagnosis, miR-126-3p (AUC = 0.760) outperformed HbA1c (AUC = 0.695), p = 0.042. These results suggest that miR-1299, -126-3p and -30e-3p are associated with prediabetes, and measuring miR-126-3p could potentially contribute to diabetes risk screening strategies.